Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Rifaximin

If you want to know more about the Rifaximin, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Rifaximin industry. More news about Rifaximin, are being released. Follow us / contact us for more Rifaximin information!
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 17 2025

    Drug Patent & Exclusivity Expiration Report - Week of Feb 17 2025

    2025-02-17

    This week, there are 7 drugs in the patent and exclusivity list. They are: - DURYSTA by AbbVie Inc, containing active ingredient Bimatoprost - IXEMPRA KIT by R-Pharm US LLC, containing active ingredient Ixabepilone - XIFAXAN by Salix Pharmaceuticals Inc, containing active ingredient Rifaximin - DIFFERIN by Galderma Laboratories LP, containing active ingredient Adapalene - NEXLIZET by Esperion Therapeutics Inc, containing active ingredient Bempedoic Acid; Ezetimibe ​- NEXLETOL by Esperion Therapeutics Inc, containing active ingredient Bempedoic Acid - XARELTO by Janssen Pharmaceuticals Inc, containing active ingredient Rivaroxaban Read More